60NANB23D160
Project Grant
Overview
Grant Description
Purpose/Scope: These funds will support the design and eventual construction of a 20-megawatt research reactor specifically designed and built to produce critical short-lived medical radioisotopes for use in diagnostic and therapeutic radiopharmaceuticals. This construction will expand capability that will compliment and strengthen the life-saving medical research being conducted at the MU NextGen Precision Health Facility by adding world-class capabilities in medical radioisotopes, nuclear medicine, and molecular imaging as well as creating a national cluster for innovation in drug discovery.
MURR NextGen will be a 20 MW research reactor specifically designed and constructed over the next decade to produce critical short-lived medical radioisotopes for use in diagnostic and therapeutic radiopharmaceuticals.
Activities to be performed: An early investment would allow for completion of the reactor design with a mandate to engage research and industry stakeholders. The study will develop the reactor design and outline functional specifications in sufficient detail to permit soliciting construction bid proposals for a state-of-the-art, next generation medical isotope production and research reactor to be built at Discovery Ridge. Some funds would also be used to help establish a core project management team of world-class professionals, dedicated to the MURR NextGen project who will begin the nuclear regulatory approval process and develop the necessary stakeholder engagement platform.
Expected outcomes: The new reactor will take on the existing supply responsibility of the aging University of Missouri Research Reactor, which is currently the sole U.S. supplier of five short-lived medical radioisotopes critical to patient diagnosis and treatment of heart disease and cancer.
Intended beneficiaries: MURR NextGen's novel design, higher power and isotope production capacity will ensure national security of supply for existing health care products and serve as a reliable platform for innovation of new cancer drugs and life sciences innovations.
Subrecipient activities: None.
MURR NextGen will be a 20 MW research reactor specifically designed and constructed over the next decade to produce critical short-lived medical radioisotopes for use in diagnostic and therapeutic radiopharmaceuticals.
Activities to be performed: An early investment would allow for completion of the reactor design with a mandate to engage research and industry stakeholders. The study will develop the reactor design and outline functional specifications in sufficient detail to permit soliciting construction bid proposals for a state-of-the-art, next generation medical isotope production and research reactor to be built at Discovery Ridge. Some funds would also be used to help establish a core project management team of world-class professionals, dedicated to the MURR NextGen project who will begin the nuclear regulatory approval process and develop the necessary stakeholder engagement platform.
Expected outcomes: The new reactor will take on the existing supply responsibility of the aging University of Missouri Research Reactor, which is currently the sole U.S. supplier of five short-lived medical radioisotopes critical to patient diagnosis and treatment of heart disease and cancer.
Intended beneficiaries: MURR NextGen's novel design, higher power and isotope production capacity will ensure national security of supply for existing health care products and serve as a reliable platform for innovation of new cancer drugs and life sciences innovations.
Subrecipient activities: None.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Columbia,
Missouri
65211-0001
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
University Of Missouri System was awarded
20MW Reactor for Medical Radioisotopes & Drug Discovery
Project Grant 60NANB23D160
worth $19,800,000
from the National Institute of Standards and Technology in September 2023 with work to be completed primarily in Columbia Missouri United States.
The grant
has a duration of 3 years and
was awarded through assistance program 11.617 Congressionally-Identified Projects.
Status
(Ongoing)
Last Modified 9/26/23
Period of Performance
9/1/23
Start Date
8/31/26
End Date
Funding Split
$19.8M
Federal Obligation
$0.0
Non-Federal Obligation
$19.8M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
60NANB23D160
SAI Number
60NANB23D160_0
Award ID URI
EXE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
1333ND DEPT OF COMMERCE NIST
Funding Office
1333ND DEPT OF COMMERCE NIST
Awardee UEI
SZPJL5ZRCLF4
Awardee CAGE
9C156
Performance District
MO-03
Senators
Joshua Hawley
Eric Schmitt
Eric Schmitt
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Construction of Research Facilities, National Institute of Standards and Technology, Commerce (013-0515) | Other advancement of commerce | Grants, subsidies, and contributions (41.0) | $19,800,000 | 100% |
Modified: 9/26/23